89 results about "Type A Monoamine Oxidase" patented technology

A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.

Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein.

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A_2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT₂ antagonist or the like), and the like.

Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed.

8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.

The invention discloses a stilbene coumarin derivative as well as a preparation method and an application thereof, and relates to the technical field of medicine synthesis. The structure general formula of the stilbene coumarin derivative is shown in formula (1) which is specified in the description. The synthesis process disclosed by the invention has the characteristics of being simple and practicable in reaction, and high in product yield; moreover, the synthesised stilbene coumarin derivative is good in inhibitory activity and selectivity on anthropogenic monoamine oxidases (hMAO-A and hMAO-B), and therefore can be used for preparing a monoamine oxidase inhibitor.

Methods for preventing or treating bruxism, including alleviating or eliminating one or more symptoms, diseases or conditions associated with or resulting from bruxism, using dopaminergic agents such as monoamine oxidase inhibitors that increase dopaminergic activity and dopamine agonists, are disclosed.

The invention relates to applications of liquidambar formosana hance fruit tannin monomer. The monomer comprises the components of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate. The invention relates to the application of the monomer in preparing a monoamine oxidase inhibitor. The invention is characterized in that the invention relates to the applications of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate in preparing medicines used for treating depression and Parkinson's disease.

The invention provides use of propargyl imine compounds in the preparation of a monoamine oxidase inhibitor and new propargyl imine compounds. The propargyl imine compounds have a structural formula (I). The invention has the advantages that: (1) equipment required for the preparation of the propargyl imine compounds is simple, the operation process is simple and convenient, the raw material sources are commercialized and readily available and the compounds serving as the monoamine oxidase inhibitor are stable in nature and high in purity (over 99 percent); and (2) compared with the traditional monoamine oxidase inhibitor, the monoamine oxidase inhibitor prepared from the new propargyl imine compounds has a simpler structure, a higher inhibition activity, higher MAO-A selectivity and higher MAO-B selectivity.

A method of treating prostate cancer in a subject with biochemically recurrent prostate cancer is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes phenelzine.

The invention discloses tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives of which the structure is shown in a general formula of a figure in the abstract. The invention simultaneously discloses the preparation method of the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives. The invention further discloses the application of the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives as a reversible and selective monoamine oxidase inhibitor drug, specifically, the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine can be applied to drugs or drug compositions for treating and preventing diseases related to aging, alzheimer's disease and parkinson's disease.

A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148- clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.

The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and/or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and/or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxymethamphetamine, or a combination thereof.

The invention discloses a purpose of a coumarin compound shown as a general formula (I) in preparation of a monoamine oxidase inhibitor, which belongs to the technical field of a medicine. Through in-vitro enzyme activity tests, the compound has good inhibition activity for monoamine oxidases A and B, and provides reference and novel thinking for developing the novel MAO inhibitor.

The invention discloses a synthetic method of a novel monoamine oxidase inhibitor (malabemide). According to the synthetic method, 5-chloro-2-pyridine carboxylic acid is taken as the primary raw material, after acyl-chlorination reactions, 5-chloro-2-pyridine formyl chloride is generated; then after amidation reactions, 5-chloro-N-(2-hydroxyethyl)-2-pyridine formyl chloride is generated, and finally 5-chloro-N-(2-hydroxyethyl)-2-pyridine formyl chloride and morpholine carry out condensation reactions to generate malabemide. Ethanolamine, 5-chloro-2-pyridine carboxylic acid, and morpholine aretaken as the main raw materials to prepare the novel monoamine oxidase inhibitor (malabemide); and the raw materials are easily available. The synthetic method has the advantages of simple operation,high product purity, and high yield, and is suitable for industrial production.

According to the invention, a monoamine oxidase inhibitor with iron ion chelating activity is synthesized, and a pyridone derivative with iron ion chelating activity and a chromone mother nucleus with MAO-B inhibitory activity are innovatively and organically combined together; the compound has remarkable advantages on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease with complex pathogenesis.

Selenium-containing benzobisfuran type compounds and preparation and applications thereof are disclosed. The structure formulas of the compounds are shown as a formula (X-a), a formula (X-b) and a formula (X-c), wherein R1 is a ketone group, an ester group or a cyano group, and R2 is C1-C6 alkyl, C1-C6 haloalkyl or aryl. A preparing route of the compounds is shown as follows. The compounds have good monoamine oxidase inhibitory activity and can be used for preparing monoamine oxidase inhibitors.